T1	Participants 59 97	cetuximab-associated acnelike eruption
T2	Participants 315 344	cetuximab-related facial rash
T3	Participants 354 512	In all, 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face
